It's How Medicine Should Be®
<< Previous | New Search | Return to Search Results | Next >>

Physician Profile

-or-

call (888) 352-RUSH for help arranging an appointment

Cynthia L. Comella, MD

Specialty:
  • Neurology
Board Certification:
  • Neurology
Faculty Rank: Professor
Medical or Graduate Education: University of Cincinnati College of Medicine
Residency: Rush University Medical Center - Neurology
Fellowship: Rush University Medical Center - Movement Disorders; Sleep Medicine
Clinical Expertise:
  • Balance disorders
  • Botulinum toxin injections
  • Cervical dystonia
  • Chorea
  • Corticobasal degeneration
  • Dementia and degenerative disease
  • Dystonia
  • Hemifacial spasm
  • Movement disorders
  • Movement disorders, fragile X-associated
  • Multiple system atrophy
  • Myoclonus
  • Parkinsonism
  • Parkinson's disease
  • Progressive supranuclear palsy (PSP)
  • Restless legs syndrome (RLS)
  • Spasmodic dysphonia
  • Stiff-person syndrome
  • Tardive dyskinesia
  • Tics
  • Tremor
  • Writer's cramp
Research Interests:
  • Dystonia: clinical features and genetics
  • Restless leg syndrome: clinical research
  • Parkinson's disease
  • Neuropsychiatric features and genetics of Parkinson's disease
  • Women's health issues and Parkinson's disease
  • Clinical trials in Parkinson's disease
  • Genetics and movement disorders
  • Pharmacological studies of movement disorders
  • Occupational dystonias
  • Clinical trials in dystonia
Google Map
  • University Neurologists
  • Professional Building
  • 1725 W. Harrison St.
  • Suite 755
  • Chicago, IL  60612
  • Phone: (312) 563-2900
  • Fax: (312) 563-2024
  • View Larger MapDriving Directions

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.

  1. Two-Year Exercise Program Improves Physical Function in Parkinson's Disease: The PRET-PD Randomized Clinical Trial.
    Prodoehl J, Rafferty MR, David FJ, Poon C, Vaillancourt DE, Comella CL, Leurgans SE, Kohrt WM, Corcos DM, Robichaud JA
    Neurorehabil Neural Repair
    2014 Jun 24
  2. Designing clinical trials for dystonia.
    Galpern WR, Coffey CS, Albanese A, Cheung K, Comella CL, Ecklund DJ, Fahn S, Jankovic J, Kieburtz K, Lang AE, McDermott MP, Shefner JM, Teller JK, Thompson JL, Yeatts SD, Jinnah HA
    Neurotherapeutics
    2014 Jan
    11(1):117-27.
  3. Cognitive and motor function in long-duration PARKIN-associated Parkinson disease.
    Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M, Ruiz D, Louis ED, Comella CL, Nance MA, Bressman SB, Scott WK, Tanner CM, Mickel SF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak KE, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Payami H, Molho E, Factor SA, Nutt JG, Serrano C, Arroyo M, Ottman R, Pauciulo MW, Nichols WC, Clark LN, Marder KS
    JAMA Neurol
    2014 Jan
    71(1):62-7.
  4. Treatment of restless legs syndrome.
    Comella CL
    Neurotherapeutics
    2014 Jan
    11(1):177-87.
  5. Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy).
    Charles PD, Adler CH, Stacy M, Comella C, Jankovic J, Manack Adams A, Schwartz M, Brin MF
    J. Neurol.
    2014 Apr 22
  6. Beyond a motor disorder: a prospective evaluation of sleep quality in cervical dystonia.
    Eichenseer SR, Stebbins GT, Comella CL
    Parkinsonism Relat. Disord.
    2014 Apr
    20(4):405-8.
  7. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial.
    Schapira AH, McDermott MP, Barone P, Comella CL, Albrecht S, Hsu HH, Massey DH, Mizuno Y, Poewe W, Rascol O, Marek K.
    Lancet Neurol. 2013
    2013 May 30. doi:pii: S1474-4422(13)70117-0. 10.1016/S1474-4422(13)70117-0. [Epub ahead of print]
  8. Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor.
    Prodoehl J, Li H, Planetta PJ, Goetz CG, Shannon KM, Tangonan R, Comella CL, Simuni T, Zhou XJ, Leurgans S, Corcos DM, Vaillancourt DE.
    Mov Disord. 2013
    2013 May 14. doi: 10.1002/mds.25491. [Epub ahead of print]
  9. A two-year randomized controlled trial of progressive resistance exercise for Parkinson's disease.
    Corcos DM, Robichaud JA, David FJ, Leurgans SE, Vaillancourt DE, Poon C, Rafferty MR, Kohrt WM, Comella CL.
    Mov Disord. 2013
    2013 Mar 27. doi: 10.1002/mds.25380. [Epub ahead of print]
  10. A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia.
    Evidente VG, Fernandez HH, Ledoux MS, Brashear A, Grafe S, Hanschmann A, Comella CL.
    J Neural Transm. 2013
    2013 Jun 19. [Epub ahead of print]
  11. Dystonia rating scales: Critique and recommendations.
    Albanese A, Sorbo FD, Comella C, Jinnah HA, Mink JW, Post B, Vidailhet M, Volkmann J, Warner TT, Leentjens AF, Martinez-Martin P, Stebbins GT, Goetz CG, Schrag A
    Mov. Disord.
    2013 Jun 15
    28(7):874-83.
  12. The focal dystonias: Current views and challenges for future research.
    Jinnah HA, Berardelli A, Comella C, Defazio G, Delong MR, Factor S, Galpern WR, Hallett M, Ludlow CL, Perlmutter JS, Rosen AR,
    Mov. Disord.
    2013 Jun 15
    28(7):926-43.
  13. Diffusion, spread, and migration of botulinum toxin.
    Ramirez-Castaneda J, Jankovic J, Comella C, Dashtipour K, Fernandez HH, Mari Z
    Mov. Disord.
    2013 Jul 18
  14. Differences in brain activation between tremor- and nontremor-dominant Parkinson disease.
    Prodoehl J, Planetta PJ, Kurani AS, Comella CL, Corcos DM, Vaillancourt DE.
    JAMA Neurol. 2013
    2013 Jan 1
    70(1):100-6. doi: 10.1001/jamaneurol.2013.582.
  15. Efficacy and Safety of IncobotulinumtoxinA in Subjects Previously Treated with Botulinum Toxin Versus Toxin-Naïve Subjects with Cervical Dystonia.
    Fernandez HH, Pappert EJ, Comella CL, Evidente VG, Truong DD, Verma A, Jankovic J.
    Tremor Other Hyperkinet Mov (N Y). 2013
    2013 Apr 18
    3. doi:pii: tre-03-140-2921-1. Print 2013.
  16. Force control deficits in individuals with Parkinson's disease, multiple systems atrophy, and progressive supranuclear palsy.
    Neely KA, Planetta PJ, Prodoehl J, Corcos DM, Comella CL, Goetz CG, Shannon KL, Vaillancourt DE.
    PLoS One. 2013
    2013
    8(3):e58403. doi: 10.1371/journal.pone.0058403. Epub 2013 Mar 11.
  17. Differences in Brain Activation Between Tremor- and Nontremor-Dominant Parkinson Disease.
    Prodoehl J, Planetta PJ, Kurani AS, Comella CL, Corcos DM, Vaillancourt DE.
    Arch Neurol. 2012
    2012 Oct 8:1-7. doi: 10.1001/archneurol.2013.582. [Epub ahead of print]
  18. Reliability of a new scale for essential tremor.
    Elble R, Comella C, Fahn S, Hallett M, Jankovic J, Juncos JL, Lewitt P, Lyons K, Ondo W, Pahwa R, Sethi K, Stover N, Tarsy D, Testa C, Tintner R, Watts R, Zesiewicz T.
    Mov Disord. 2012
    2012 Oct
    27(12):1567-9. doi: 10.1002/mds.25162. Epub 2012 Oct 2.
  19. Tai chi for patients with Parkinson's disease.
    Corcos DM, Comella CL, Goetz CG.
    N Engl J Med. 2012
    2012 May 3
    366(18):1737-8; author reply 1738. doi: 10.1056/NEJMc1202921#SA2. No abstract available.
  20. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia.
    Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S; U.S. XEOMIN Cervical Dystonia Study Group.
    J Neurol Sci. 2011
    2011 Sep 15
    308(1-2):103-9. doi: 10.1016/j.jns.2011.05.041. Epub 2011 Jul 18.
  21. Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE).
    Jankovic J, Adler CH, Charles PD, Comella C, Stacy M, Schwartz M, Sutch SM, Brin MF, Papapetropoulos S.
    BMC Neurol. 2011
    2011 Nov 4
    11:140. doi: 10.1186/1471-2377-11-140.
  22. Pre-operative evaluations for DBS in dystonia.
    Thobois S, Taira T, Comella C, Moro E, Bressman S, Albanese A.
    Mov Disord. 2011
    2011 Jun
    26 Suppl 1:S17-22. doi: 10.1002/mds.23481. Review.
  23. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial.
    Jankovic J, Comella C, Hanschmann A, Grafe S.
    Mov Disord. 2011
    2011 Jul
    26(8):1521-8. doi: 10.1002/mds.23658. Epub 2011 Apr 22.
  24. Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study.
    Caccappolo E, Alcalay RN, Mejia-Santana H, Tang MX, Rakitin B, Rosado L, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner CM, Mickel SF, Andrews HF, Waters C, Fahn S, Cote LJ, Frucht S, Ford B, Rezak M, et al.
    J Int Neuropsychol Soc. 2011
    2011 Jan
    17(1):91-100. doi: 10.1017/S1355617710001190. Epub 2010 Nov 24.
  25. Dystonias of the head and neck: An overview.
    Charous SJ, Comella C.
    Ear Nose Throat J. 2011
    2011 Feb
    90(2):E4. Review.
  26. Jaw-opening dystonia: Quality of life after botulinum toxin injections.
    Charous SJ, Comella CL, Fan W.
    Ear Nose Throat J. 2011
    2011 Feb
    90(2):E9.
  27. Sleep disorders in Parkinson's disease.
    Videnovic A, Comella CL.
    Handb Clin Neurol. 2011
    2011
    99:997-1010. doi: 10.1016/B978-0-444-52007-4.00019-9. No abstract available.
  28. Early-onset primary dystonia.
    Robottom BJ, Weiner WJ, Comella CL.
    Handb Clin Neurol. 2011
    2011
    100:465-79. doi: 10.1016/B978-0-444-52014-2.00036-7. Review.
  29. Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study.
    Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Ross BM, Verbitsky M, Kisselev S, Louis ED, Comella C, Colcher A, Jennings D, Nance MA, Bressman SB, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Cote L, Frucht S, et al.
    Arch Neurol. 2010
    2010 Sep
    67(9):1116-22. doi: 10.1001/archneurol.2010.194.
  30. Blood oxygenation level-dependent activation in basal ganglia nuclei relates to specific symptoms in de novo Parkinson's disease.
    Prodoehl J, Spraker M, Corcos D, Comella C, Vaillancourt D.
    Mov Disord. 2010
    2010 Oct 15
    25(13):2035-43. doi: 10.1002/mds.23360.
  31. Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study.
    Marder KS, Tang MX, Mejia-Santana H, Rosado L, Louis ED, Comella CL, Colcher A, Siderowf AD, Jennings D, Nance MA, Bressman S, Scott WK, Tanner CM, Mickel SF, Andrews HF, Waters C, Fahn S, Ross BM, Cote LJ, Frucht S, Ford B, Alcalay RN, et al.
    Arch Neurol. 2010
    2010 Jun
    67(6):731-8. doi: 10.1001/archneurol.2010.95.
  32. Scales to assess sleep impairment in Parkinson's disease: critique and recommendations.
    Högl B, Arnulf I, Comella C, Ferreira J, Iranzo A, Tilley B, Trenkwalder C, Poewe W, Rascol O, Sampaio C, Stebbins GT, Schrag A, Goetz CG.
    Mov Disord. 2010
    2010 Dec 15
    25(16):2704-16. doi: 10.1002/mds.23190. Review.
  33. Olfaction in Parkin heterozygotes and compound heterozygotes: The CORE-PD study
    Alcalay RN, Siderowf A, Ottman R, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Louis E, Ruiz D, Waters C, Fahn S, Cote L, Frucht S, Ford B, Orbe-Reilly M, Ross B, Verbitsky M, Kisselev S, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Rezak M, Novak KE, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Clark LN, Marder K
    Neurology
    2010 Dec 29
  34. Basal ganglia hypoactivity during grip force in drug naïve Parkinson's disease.
    Spraker MB, Prodoehl J, Corcos DM, Comella CL, Vaillancourt DE.
    Hum Brain Mapp. 2010
    2010 Dec
    31(12):1928-41. doi: 10.1002/hbm.20987. Epub 2010 Mar 11.
  35. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo.
    Menza M, Dobkin RD, Marin H, Gara M, Bienfait K, Dicke A, Comella CL, Cantor C, Hyer L.
    Mov Disord. 2010
    2010 Aug 15
    25(11):1708-14. doi: 10.1002/mds.23168.
  36. Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study.
    Schapira AH, Albrecht S, Barone P, Comella CL, McDermott MP, Mizuno Y, Poewe W, Rascol O, Marek K.
    Mov Disord. 2010
    2010 Aug 15
    25(11):1627-32. doi: 10.1002/mds.23143.
  37. Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease.
    Alcalay RN, Mejia-Santana H, Tang MX, Rakitin B, Rosado L, Ross B, Verbitsky M, Kisselev S, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, et al.
    J Clin Exp Neuropsychol. 2010
    2010 Aug
    32(7):775-9. doi: 10.1080/13803390903521018. Epub 2010 Feb 24.
  38. Treatment of focal dystonias with botulinum neurotoxin.
    Hallett M, Benecke R, Blitzer A, Comella CL.
    Toxicon. 2009
    2009 Oct
    54(5):628-33. doi: 10.1016/j.toxicon.2008.12.008. Epub 2008 Dec 13. Review.
  39. Variability of EMG patterns: a potential neurophysiological marker of Parkinson's disease?
    Robichaud JA, Pfann KD, Leurgans S, Vaillancourt DE, Comella CL, Corcos DM.
    Clin Neurophysiol. 2009
    2009 Feb
    120(2):390-7. doi: 10.1016/j.clinph.2008.10.015. Epub 2008 Dec 11.
  40. Stimulation-induced parkinsonism after posteroventral deep brain stimulation of the globus pallidus internus for craniocervical dystonia.
    Zauber SE, Watson N, Comella CL, Bakay RA, Metman LV.
    J Neurosurg. 2009
    2009 Feb
    110(2):229-33. doi: 10.3171/2008.6.17621.
  41. Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease.
    Alcalay RN, Mejia-Santana H, Tang MX, Rosado L, Verbitsky M, Kisselev S, Ross BM, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, et al.
    Arch Neurol. 2009
    2009 Dec
    66(12):1517-22. doi: 10.1001/archneurol.2009.267.
  42. Treatment of early Parkinson's disease. Part 2.
    Simuni T, Lyons KE, Pahwa R, Hauser RA, Comella C, Elmer L, Weintraub D.
    Eur Neurol. 2009
    2009
    61(4):206-15. doi: 10.1159/000197104. Epub 2009 Jan 29. Review.
  43. Treatment of early Parkinson's disease. Part 1.
    Simuni T, Lyons KE, Pahwa R, Hauser RA, Comella C, Elmer L, Weintraub D.
    Eur Neurol. 2009
    2009
    61(4):193-205. doi: 10.1159/000197103. Epub 2009 Jan 29. Review.
  44. Sleep disorders in Parkinson's disease.
    Comella CL.
    Curr Treat Options Neurol. 2008
    2008 May
    10(3):215-21.
  45. Parkinson's disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment.
    Weintraub D, Comella CL, Horn S.
    Am J Manag Care. 2008
    2008 Mar
    14(2 Suppl):S40-8. Review.
  46. Parkinson's disease--Part 2: Treatment of motor symptoms.
    Weintraub D, Comella CL, Horn S.
    Am J Manag Care. 2008
    2008 Mar
    14(2 Suppl):S49-58. Review.
  47. Parkinson's disease--Part 3: Neuropsychiatric symptoms.
    Weintraub D, Comella CL, Horn S.
    Am J Manag Care. 2008
    2008 Mar
    14(2 Suppl):S59-69. Review.
  48. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay.
    Brin MF, Comella CL, Jankovic J, Lai F, Naumann M; CD-017 BoNTA Study Group.
    Mov Disord. 2008
    2008 Jul 30
    23(10):1353-60. doi: 10.1002/mds.22157.
  49. Changes in the relationship between movement velocity and movement distance in primary focal hand dystonia.
    Prodoehl J, Corcos DM, Leurgans S, Comella CL, Weis-McNulty A, MacKinnon CD.
    J Mot Behav. 2008
    2008 Jul
    40(4):301-13. doi: 10.3200/JMBR.40.4.301-314.
  50. The treatment of cervical dystonia with botulinum toxins
    Comella CL
    J Neural Transm
    2008
    115(4):579-83
  51. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial.
    Truong D, Comella C, Fernandez HH, Ondo WG; Dysport Benign Essential Blepharospasm Study Group.
    Parkinsonism Relat Disord. 2008
    2008
    14(5):407-14. doi: 10.1016/j.parkreldis.2007.11.003. Epub 2008 Mar 5.
  • (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
  • View Transcript